Intranasal drug developer Orexo and Swedish vaccine developer Abera Bioscience have announced that they will collaborate on development of intranasal dry powder vaccines based on Orexo’s AmorphOX powder engineering technology and Abera’s vaccine platform, starting with an influenza vaccine. Abera will fund the project using grant money it has received from the Coalition for Epidemic Preparedness Innovation (CEPI) and other organizations.
In July 2024, Orexo received a CRL to its NDA for OX124 intranasal dry powder naloxone. The company’s pipeline also includes intranasal dry powder nalmefene (OX125) and epinephrine (OX640). Abera’s lead candidate is Ab-01.12, an intranasal vaccine against pneumococcus that is ready to advance into clinical development, according to the Abera web site.
Orexo Senior VP and Head of R&D Robert Rönn commented, ”Abera has an innovative and promising vaccine platform for the development of mucosal vaccines, as confirmed by their recent funding from CEPI. The collaboration is fully in line with our strategic development of the AmorphOX platform and through collaborations we can showcase the potential and value of our technology. We look forward to working with Abera, where our experience and technologies are highly complementary.”
Abera Bioscience CEO Maria Alriksson said, ”Orexo has an impressive knowledge and technology for powder formulations of medicines that perfectly complements our expertise in vaccine development. Their innovative technology, AmorphOX, has shown to improve the properties of a wide range of different active ingredients. There is therefore great potential in this area, and we will be able to take many important development steps in the coming year.”
Read the Orexo press release.
